Phio Pharmaceuticals Corp. announced the addition of three clinical trial sites for its Phase 1b study of PH-762: The George Washington University?Medical Faculty Associates in Washington, D.C. Banner MD Anderson Cancer Center in Gilbert, Arizona. Integrity Research Clinical Associates in Delray Beach, Florida.

PH-762 is an INTASYL compound that silences PD-1, a protein that inhibits T cells? ability to kill cancer cells. The Phase 1b trial is a non-comparative study of neoadjuvant monotherapy using PH-762 in adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.

The study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.